The polymyalgia rheumatica drugs industry is experiencing a robust upswing driven by rising prevalence of inflammatory conditions among aging populations. Polymyalgia Rheumatica Drugs Market line with the title, this analysis explores how treatment innovations and strategic realignments are shaping